The Medicines and Healthcare products Regulatory Agency (MHRA) is the executive Agency of the Department of Health and Social Care that acts on behalf of the Ministers to protect and promote public health and patient safety, by ensuring that medicines, medical devices and blood components for transfusion meet appropriate standards of safety, quality and efficacy in the UK.

One of the MHRAs priorities is to engage and network more with healthcare professionals, patients and the public, including by working jointly with others in the health and social care system.

The MHRA has strong/effective working relationships with stakeholders such as BSIR to ensure the patient safety by encouraging reporting of safety concerns, aiding decision making and listening to concerns. An MHRA representative sits on the Safety and Quality Subcommittee.

 

 

Updated guidance on the use of paclitaxel coated devices

The MHRA has just published updated guidance on the use of paclitaxel coated devices for the treatment of patients with peripheral arterial disease.

You can view the updated guidance is here.

The document removes any residual restrictions on the use of these devices for your patients.

This includes the removal of prior MHRA instructions for follow-up but recommends that all treated patients are entered into the National Vascular Registry database, as all patients that you treat for PAD should be.

February 2024

 

MHRA update on COVID-19

Please click HERE for recently published MHRA guidance on coronavirus (COVID 19) aimed at supporting healthcare partners.